ArticleEuropean journal of medical research2025
Solute carrier-correlated gene signature in predicting the prognosis and immunity in patients with acute myeloid leukemia.
Article in European journal of medical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Investigation of the expression and potential mechanistic role of BYSL in acute myeloid leukemia.Clinical and experimental medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSolute carrier (SLC) is involved in diverse malignancies. This research analyzed the involvement of SLC-related genes in acute myeloid leukemia (AML).
methodsThis study analyzed transcriptomic and clinical data from The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO), with SLC-related genes from GeneCards. SLC scores were obtained using single-sample gene set enrichment analysis (ssGSEA), and key modules were identified with weighted gene co-expression network analysis (WGCNA). Functional enrichment was performed using the clusterProfiler package. Prognostic genes were screened by univariate Cox and Least Absolute Shrinkage and Selection Operator (LASSO) regression, and a RiskScore model was built. Tumor immune microenvironment features were assessed by Gene Set Variation Analysis (GSVA) and the ESTIMATE algorithm. Mutation profiles and pathways were compared between risk groups, and hub gene expression and function were validated by quantitative real-time polymerase chain reaction (qRT-PCR) and cell counting kit-8 (CCK-8) assay.
resultsThis study identified the turquoise module significantly associated with the SLC score using WGCNA, and enrichment analysis showed immune-related pathways. A RiskScore model (FERMT3, CLCN5, DUSP7, and CSRP1) was constructed. High-risk patients showed significantly worse survival, and a stronger prognostic efficacy was seen in the model proposed in this study with an overall C-index of 0.626. Immune profiling revealed higher immune cell infiltration and checkpoint expression in the high-risk group. Additionally, the genes with higher mutation rates in the high-risk group were DNMT3A, RUNX1, and NPM1. The RiskScore showed significant positive correlations with multiple oncogenic signaling pathways, such as EGFR and MAPK. In-vitro cell assays demonstrated that FERMT3 and CLCN5 were significantly upregulated in AML cell lines, and gene knockout significantly inhibits cell viability.
conclusionOverall, these SLC-related genes may have predictive relevance in AML, and our study identified some promising targets for AML.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.